tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
ARQT
Arcutis Biotherapeutics
RESEARCH TOOLSreports

Arcutis Biotherapeutics (ARQT) Stock News & Sentiment

Compare
954 Followers
Buy Rating on Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
Premium
Ratings
Buy Rating on Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
18d ago
ARQT
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
18d ago
ARQT
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
Premium
Ratings
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
1M ago
ARQT
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
Premium
Company Announcements
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
2M ago
8K
ARQT
Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
Premium
Company Announcements
Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
3M ago
ARQT
Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
3M ago
ARQT
Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating
Premium
Ratings
Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating
3M ago
ARQT
More ARQT News >

ARQT News on the Web

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)
TipRanks News
Bullish
Jefferies Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT)
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)
TipRanks News
Bullish
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT) and Arcutis Biotherapeutics (ARQT)
TipRanks News
Bullish
Arcutis Biotherapeutics (ARQT) Sees Target Price Boost from Needham | ARQT Stock News
GuruFocus News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT) and Sarepta Therapeutics (SRPT)
TipRanks News
Bullish
Arcutis Biotherapeutics (ARQT) Takes Over ZORYVE Promotion
GuruFocus News
Bullish
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
ARQT
Sector Average
Media Buzz
This Week8 articles
Weekly Average3.5 articles
News Sentiment
This Week100%
Sector Average73%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARQT’s Media Buzz Sentiment?
8 articles about ARQT were published this week. In an average week, 3.5 articles are published.
    What is ARQT’s weekly average amount of articles?
    In an average week, 3.5 articles about ARQT are published.
      What is ARQT’s News Sentiment?
      100% of articles about ARQT were positive this week, compared to its sector average of 73%.
        Healthcare Stocks that are Trending in the News
        IMAImageneBio
        HOCPFHOYA
        CBLControl Bionics Ltd.
        CRDFCardiff Oncology
        QNCXQuince Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week